ArticleOpen forum infectious diseases2026

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.

Onyema Ogbuagu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.